ETF Financing Ranking | GF CSI Innovative Drugs Industry ETF (515120) had a net financing buy-in of CNY 14.5 million, ranked first among comparable funds-20260901
NewTimeSpace (newtimespace.com) News,Sep 1, 2026, GF CSI Innovative Drugs Industry ETF (515120.SH) had a turnover of CNY 417.14 million. Obtained financing buy-in of CNY 63.26 million, and financing repayment of CNY 48.76 million, with a net financing buy-in of CNY 14.5 million, ranked first among comparable funds. (Data source: Wind)
Over a longer period, had leveraged funds with continuous inflow over the last 2 days, with a total inflow of CNY 58.64 million, ranked first among comparable funds. (Data source: Wind)
GF CSI Innovative Drugs Industry ETF (515120.SH), off-exchange connection (A type: 012737; C type: 012738; F type: 022104).
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- GF CSI Innovative Drugs Industry ETF (515120) fell 1.87%, with AUM increasing by RMB 2.478 billion over the past three months
- GF CSI Innovative Drugs Industry ETF (515120) rose 2.18%, with its scale increasing by RMB 78.1496 million over the past 1 week
- GF CSI Innovative Drugs Industry ETF (515120) Rises 2.47%, with Scale Growing by RMB 393 Million Over the Past Week
- GF CSI Innovative Drugs Industry ETF (515120) Rises 3.24%, with Scale Growing by RMB 636 Million Over the Past Week
- GF CSI Innovative Drugs Industry ETF(515120) Falls 1.23%, with Latest Net Capital Outflow of RMB 89.0930 Million